Cardiovascular Risk Management

Patient Assessment and Risk Stratification

The American College of Cardiology/American Heart Association (ACC/AHA) guideline identifies family history of premature ASCVD and elevated lipoprotein(a) ≥50 mg/dL as risk-enhancing factors, which are present in patients with a family history of coronary artery disease and an Lp(a) level of ≥50 mg/dL 1, 2
Coronary artery calcium (CAC) scoring may be valuable in improving risk stratification in intermediate-risk adults, with a CAC score ≥100 or ≥75th percentile strongly favoring statin initiation 1, 2
Even with a CAC score of zero, statin therapy may still be warranted given the strong family history of CAD and markedly elevated Lp(a) 1
The traditional threshold for elevated Lp(a) is >30 mg/dL, and patients with Lp(a) >50 mg/dL should be re-stratified into a higher risk category, as stated by the American College of Cardiology 3

The ACC/AHA guideline recommends initiating moderate-intensity statin therapy as first-line treatment, with a target of ≥30% reduction in LDL-C 2
If LDL-C targets are not achieved, adding ezetimibe 10 mg daily may be considered, with reassessment in 4-6 weeks 4
For persistent elevation or progression, considering a PCSK9 inhibitor if LDL-C remains elevated despite maximum tolerated statin plus ezetimibe may be necessary 5
Regular monitoring of lipid profile every 3-12 months and periodic reassessment of cardiovascular risk are recommended 2
Lipoprotein(a) [Lp(a)] reduction is crucial for managing cardiovascular disease risk, with niacin being the most effective approved medication, providing a 30-35% reduction in Lp(a) levels at doses up to 2000 mg/day, as recommended by the European Society of Cardiology 6
PCSK9 Inhibitors (evolocumab, alirocumab) have an efficacy of 20-30% reduction in Lp(a) levels, with a mechanism of enhanced LDLR-mediated clearance of Lp(a), as noted by the American College of Cardiology 3

Healthy lifestyle modifications, including regular physical activity, heart-healthy diet, maintaining healthy weight, and avoiding tobacco products, remain important regardless of Lp(a) levels 6
Screening first-degree relatives for elevated Lp(a) and other lipid abnormalities may be considered given the hereditary nature of this condition 7
Patients with premature cardiovascular disease, family history of premature CVD, recurrent or rapidly progressive vascular disease despite lipid-lowering therapy, familial hypercholesterolemia, low HDL-C, diabetes mellitus, or autoimmune diseases should be considered for Lp(a) measurement, as recommended by the European Society of Cardiology and the American College of Cardiology 6, 3
Lifestyle modifications have minimal effect on Lp(a) levels, unlike other lipid parameters, as suggested by the American Heart Association and reported by the European Heart Journal and Praxis Medical Insights guidelines 6, 8

Niacin (Nicotinic Acid) reduces Lp(a) levels by 30-35% through interference with apo(a) transcription, with a dosing of up to 2000 mg/day, as approved by the FDA 6, 9
Fibrates (particularly gemfibrozil) reduce Lp(a) levels by up to 20%, with best results seen with gemfibrozil, according to the European Heart Society 6
Acetylsalicylic acid (Aspirin) reduces Lp(a) levels by 10-20% and can be considered as adjunctive therapy to niacin, as recommended by the European Society of Cardiology 6
L-Carnitine reduces Lp(a) levels by 10-20% through its mechanism as a mitochondrial fatty acid transporter, as noted by the European Heart Society 6
Hormone therapies (estrogens, testosterone, tibolone) reduce Lp(a) levels by up to 37%, 30-40%, and 35%, respectively, but are not recommended solely for Lp(a) reduction due to other risks, as stated by the European Society of Cardiology 6
Thyroid hormone replacement can normalize elevated Lp(a) levels in hypothyroid patients, as recommended by the European Thyroid Association 6
Lipoprotein apheresis reduces Lp(a) levels by up to 80% and is indicated for patients with recurrent CVD events despite maximal therapy or Lp(a) >60 mg/dL with ongoing CVD, as recommended by the European Atherosclerosis Society 6
Antisense oligonucleotides (e.g., pelacarsen) and small interfering RNAs (e.g., olpasiran) show promising results with 40-90% reduction in Lp(a) levels, but are still in clinical development 6

Children with elevated Lp(a) have a fourfold increased risk of acute ischemic stroke, and a >10-fold increased risk of recurrent ischemic stroke with Lp(a) >90th percentile, as reported by the American College of Cardiology 3
Lp(a) is two- to three-fold elevated in hemodialysis patients and those with renal disease, requiring particular attention and possibly more aggressive management, according to the European Society of Cardiology 6
Regular monitoring for side effects of niacin therapy, including flushing, hyperglycemia, hepatotoxicity, and hyperuricemia, is recommended 6
Re-assessing cardiovascular risk regularly is necessary, as elevated Lp(a) contributes to residual risk even when other risk factors are controlled 6